Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $493.0K | $1.1M | $1.3M |
| Cost of revenue | $0 | $0 | $0 | $1.7M | $2.4M | $7.0M |
| Gross profit | $0 | $0 | $0 | −$1.2M | −$1.4M | −$5.7M |
| Gross margin | — | — | — | -251.3% | -126.4% | -452.3% |
| R&D | $28.6M | $35.6M | $20.1M | $9.1M | $3.1M | $5.9M |
| Operating income | −$61.1M | −$73.5M | −$32.5M | −$74.8M | −$19.0M | −$35.7M |
| EBITDA | −$35.4M | −$56.1M | $480.0K | −$74.8M | −$48.0M | −$35.6M |
| Net income | −$61.1M | −$73.7M | −$18.0M | −$76.1M | −$19.8M | −$58.8M |
| Net margin | — | — | — | -15436.1% | -1830.5% | -4633.2% |
| EPS (diluted) | -9420.73 | -11361.35 | -2695.87 | -5715.36 | -361.16 | -177.30 |
Annual figures · source: Financial Modeling Prep
No one on the platform currently holds BXRX.
No tracked institution reports a position in BXRX as of their last filing.
| Execution date | Ratio |
|---|---|
| 2022-12-01 | 1-for-40reverse |
| 2022-09-28 | 1.001-for-1 |
| 2022-02-16 | 1-for-35reverse |
No one on the platform has traded BXRX yet.
| $956000 |
| — |
| INFIQInfinity Pharmaceuticals, Inc. | $0.00 | +0.00% | $9076 | — |
| LSDILucy Scientific Discovery Inc. | $0.51 | -23.29% | $906910 | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.